【摘要】 目的评价呼吸道感染的4种治疗方案的药物经济学效果。方法采用回顾性研究方法,选择114例呼吸道感染患者,按治疗方案分为4组(A,B,C,D组),分别观察其疗效并运用成本-效果分析法(CEA)进行分析。结果4组治疗方案成本分别为190.40,403.20,1380.96,174.72元,临床有效率分别为86.7%,86.7%,90.0%,62.5%,成本-效果比(C/E)分别为2.19,4.65,15.34,2.79,A,B,C组相对于D组的增量成本-效果比(ΔC/ΔE)分别为0.65,9.44,43.86。结论A组(头孢曲松组方案)为最佳的治疗方案。更多还原

【Abstract】 Objective To evaluate the pharmacoeconomic effectiveness of the four therapeutic schemes for respiratoy tract infections.Methods A retrospective study was conducted,in which a total of 114 cases with respiratory tract infection were enrolled and randomly assigned to receive each of the following 4 therapies(group A,B,C,D).The therapeutic effects were monitored and the cost-effectiveness analysis was adopted on the four treatment schemes.Results The costs of the four regimens were 190.40 yuan,403.20 yuan,1380.96 yuan and 174.72 yuan.The clinical effective rates were 86.7%,86.7%,90.0% and 62.5%,respectively.The cost-effectiveness rates(C/E)were 2.19,4.65,15.34 and 2.79,respectively.And the incremental cost-effectiveness rates(ΔC/ΔE)of group A,B and C were 0.65,9.44 and 43.86 respectively,as against group D.Conclusion Group A(ceftriaxone treatment group)is the best therapeutic scheme.更多还原